CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
romiplostimbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02052882
NCT02052882Phase 2Completed
CompareCT.gov

An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia

Memorial Sloan Kettering Cancer Center·interventional·Posted Feb 3, 2014·Updated Dec 27, 2024

In Brief

A Phase 2 clinical trial evaluating romiplostim for Isolated Chemotherapy-induced Thrombocytopenia. Completed, enrolled 60 participants across 6 sites.

Detailed Summary

This study is to determine if using weekly romiplostim injections will improve the patient's platelet count more effectively than simply waiting for the platelets to improve on its own, and if romiplostim will also allow the patient to receive at least 2 further cycles of chemotherapy without thrombocytopenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIsolated Chemotherapy-induced Thrombocytopenia
CountriesUnited States
CollaboratorsAmgen

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 3, 2014
Enrollment StartJan 30, 2014
Primary CompletionNov 13, 2023
TodayJul 2, 2026
Enrollment to primary: 9.8 yearsPosted 12.4 years ago

Interventions

romiplostimbiological